Ann: FY21 Results Presentation, page-42

Update from Apiam Animal Health ( ASX:AHX) on Animal Health

From AHX annual report -Managing Directors Report p6

Trials continued during the year in relation to the ZoonoMicrobe Shield product for which we have

the exclusive licence for veterinary and agriculturalapplications in the USA.

The application of Zoono Microbe Shield has been demonstrated after 21 days applied to a surface to provide a

significant reduction in the levels of porcine epidemic diarrhoea virus (PEDv) and porcine

reproduction and respiratory syndrome virus (PRRSv), which are significant issues in the North

American pig industry.

This study was undertaken by an independent US university.
These results provide the potential for a significant market opportunity, and Apiam has entered into an
agreement with a US pharmaceutical company to expand its sales and marketing footprint to the
US veterinary market, expected to commence in Q2 of FY22.

https://www.asx.com.au/asxpdf/20210830/pdf/44zwt2z51mxrsq.pdf